| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Cytek Biosciences, Inc.
$4.81
-0.1 (-2.15%)
Market Cap
625.22 M
EPS
-0.62
P/E Ratio
-
Value Trade
5.47 M
1.48 %
Week
5.48 %
1 Month
21.16 %
3 Month
9.57 %
6 Month
-80.05 %
5 Year
-80.05 %
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
820.26 K
52 Week Range
3.28 - 6.18
% held by Insiders
8.43 %
% held by Institutions
63.19 %
Enterprise Value
363.22 M
Total Shares
129.98 M
Short %
4.11 %
Float Shares
115.54 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
CTKB Clinical Trial Results & History
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CTKB
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
CTKB Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
CTKB▼ -2.1%today
Jury Finds in Cytek’s Favor on Three of Four Asserted Claims; Company to Challenge Remaining Finding
Cytek Biosciences won a jury verdict in a patent infringement case, with the jury favoring Cytek on three of four claims. The company plans to contest the remaining finding of infringement and the associated damages of $56 million. Despite this, Cytek's product offerings remain unaffected, and the company is committed to its innovative Full Spectrum Profiling technology.
Read more →CTKBCytek Biosciences Reports Second Quarter 2026 Financial Results
Cytek Biosciences reported a 6% increase in total revenue for Q2 2026, reaching $48.1 million. The company launched new products, including the Cytek Borealis flow cytometer, and saw growth in recurring revenue. However, operating expenses rose significantly, leading to a net loss of $12.2 million. The company updated its full-year revenue guidance to between $207 million and $212 million.
Read more →CTKBCytek Biosciences to Report Second Quarter 2026 Financial Results on August 5, 2026
Cytek Biosciences, Inc. will announce its second quarter 2026 financial results on August 5, 2026. A conference call will follow to discuss the results and the company's business outlook. The event underscores Cytek's commitment to transparency and investor engagement.
Read more →CTKBCytek® Biosciences Opens New Innovation Center in Bellevue to Advance R&D and Customer Engagement
Cytek Biosciences has opened a new innovation center in Bellevue, Washington, relocating from Seattle. The facility is designed to enhance research and development while promoting collaboration and customer engagement. It includes R&D laboratories, training areas, and employee-focused amenities. This move reflects Cytek's commitment to advancing scientific discovery and innovation.
Read more →CTKBSingapore Clinical Research Institute (SCRI) Clinical Trials Symposium 2026
The Singapore Clinical Research Institute (SCRI) is set to host its Clinical Trials Symposium in 2026. This event aims to foster collaboration among researchers and industry professionals in the field of clinical trials. Attendees will have opportunities to engage with experts and discuss the latest advancements in clinical research.
Read more →CTKBAustralian and New Zealand Society for Immunology (ASI) and Immunology Group of Victoria (IgV) Annual Scientific Meeting 2026
The Australian and New Zealand Society for Immunology (ASI) and the Immunology Group of Victoria (IgV) are set to host their Annual Scientific Meeting in 2026. This event aims to bring together immunology experts to discuss recent developments and innovations in the field. Attendees can expect a rich program featuring presentations, workshops, and networking opportunities.
Read more →CTKBAustralian and New Zealand Society for Immunology (ASI) NZ Branch Meeting 2026
The Australian and New Zealand Society for Immunology (ASI) is set to hold its NZ Branch Meeting in 2026. This event will focus on advancements in immunology, particularly in immuno-oncology and related research areas. It aims to enhance collaboration among professionals in the field and provide a platform for networking and sharing knowledge.
Read more →CTKBSpectral Flow Cytometry Symposium
The Spectral Flow Cytometry Symposium features Cytek's latest advancements in flow cytometry technologies, including the Cytek Borealis and Aurora systems. It emphasizes applications in immuno-oncology, infectious diseases, and drug discovery. The event aims to enhance understanding and utilization of these technologies in research and clinical settings.
Read more →CTKB4th Annual Center for Human Immunobiology (CHI) Scientific Retreat
The 4th Annual Center for Human Immunobiology (CHI) Scientific Retreat focuses on the latest advancements in immunobiology. It aims to foster collaboration among researchers in the field. Attendees will explore various applications, including immuno-oncology and drug discovery.
Read more →CTKBInternational Society for Stem Cell Research (ISSCR) 2026 Annual Meeting
The International Society for Stem Cell Research (ISSCR) will hold its 2026 Annual Meeting, focusing on advancements in stem cell research. The event will cover various applications, including immuno-oncology and drug discovery. Attendees will have opportunities for training and validation services, enhancing their research capabilities.
Read more →CTKBCytek Biosciences to participate at the Singular Research’s Las Vegas Invitational Conference
Cytek Biosciences, Inc. announced its participation in the Singular Research’s Las Vegas Invitational Conference from June 14-16, 2026. The company's management will present on June 15 at 11:00 a.m. PT. Interested parties can access the presentation via a live and archived webcast on the company's investor website.
Read more →CTKBCytek Biosciences to Unveil Next-Generation Spectral Flow Cytometry Innovations at CYTO 2026
Cytek Biosciences will showcase its new 7-laser Cytek Borealis full spectrum flow cytometer and enhanced Cytek Aurora Evo system at CYTO 2026. These innovations aim to improve flexibility, scalability, and efficiency in cell analysis. The Borealis system features advanced optical capabilities and integrated imaging, while the Aurora Evo updates focus on automation to support biopharma research.
Read more →CTKBAustralasian B Cell Dialogue (ABCD+)
The Australasian B Cell Dialogue (ABCD+) emphasizes the latest developments in B cell research and its applications in immuno-oncology. The event showcases various products and services aimed at enhancing research workflows. It aims to foster collaboration among researchers and industry leaders in the field.
Read more →CTKB53rd Annual Conference of Indian Immunology Society (IMMUNOCON 2026)
The 53rd Annual Conference of the Indian Immunology Society, known as IMMUNOCON 2026, is set to highlight significant advancements in the field of immunology. This event will serve as a key platform for researchers to collaborate and share insights on various topics, including immuno-oncology and infectious diseases. Attendees can expect to engage in discussions that will shape the future of immunological research.
Read more →CTKB16th Società Italiana di Immunologia / Immunologia Clinica e Allergologia (SIICA) National Congress
The 16th Società Italiana di Immunologia / Immunologia Clinica e Allergologia (SIICA) National Congress is set to showcase the latest advancements in immunology and clinical practices. This event will facilitate networking opportunities for professionals and emphasize innovative research areas such as immuno-oncology and drug discovery. Participants can expect a comprehensive agenda covering various applications and products in the field.
Read more →CTKBFederation of Clinical Immunology Societies (FOCIS) 2026 Annual Meeting
The Federation of Clinical Immunology Societies (FOCIS) is set to host its 2026 Annual Meeting, focusing on advancements in clinical immunology. The event will feature discussions on immuno-oncology, infectious diseases, and inflammatory diseases. Attendees will have the chance to network with industry experts and explore innovative research areas.
Read more →CTKBImmunologyLA 2026
The article discusses the various products and services offered by Cytek, including their advancements in immunology and related research areas. It highlights their range of flow cytometry products and reagents, as well as training and validation services. The company also emphasizes its commitment to research in immuno-oncology, infectious diseases, and inflammatory diseases.
Read more →CTKBCYTO 2026
Cytek is actively expanding its range of products and services, including innovations in immuno-oncology and other research areas. The company offers a variety of reagents and software solutions aimed at enhancing drug discovery and genomics. Additionally, Cytek emphasizes training and validation services to support its offerings.
Read more →CTKBCytek Biosciences Reports First Quarter 2026 Financial Results
Cytek Biosciences reported a 6% increase in total revenue for Q1 2026, reaching $44.1 million. Service revenue grew by 15%, contributing to a rise in recurring revenue to 35% of total revenue. However, the company experienced an increase in operating expenses and a higher net loss compared to the previous year. Cytek reaffirms its revenue guidance for 2026.
Read more →CTKB▼ -8.4%on this news
Cytek Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026
Cytek Biosciences, Inc. will announce its financial results for Q1 2026 on May 7, 2026. A conference call will follow to discuss the results and future outlook. The company specializes in advanced cell analysis solutions, utilizing its patented Full Spectrum Profiling technology. Investors can access the webcast via the company's website.
Read more →CTKBCytek Biosciences Celebrates One Year of Operations at Singapore Facility, Accelerating Growth and Regional Impact
Cytek Biosciences has completed its first year of operations at its 8,500-square-foot facility in Singapore, marking a significant milestone in its expansion efforts in the Asia-Pacific region. The facility has improved Cytek's manufacturing capacity and regional service capabilities while also enhancing global supply chain resilience. Driven by increasing demand for cellular analysis solutions, the expansion is expected to support sustained business growth in this key market. Cytek's commitment to local partnerships aims to drive innovation and talent development in Singapore's MedTech ecosystem.
Read more →CTKBCytek Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook
Cytek Biosciences reported its fourth quarter and full year 2025 financial results, highlighting an 8% revenue increase in Q4, driven by strong instrument sales. However, the company also faced a net loss of $44.1 million in Q4 2025, a significant decline from profits in the previous year. Operating expenses surged by 25.5%, contributing to a full year net loss of $66.5 million. Looking ahead, Cytek projects a revenue increase for 2026, targeting between $205 million to $212 million.
Read more →CTKBCytek Biosciences to participate at the TD Cowen 46th Annual Health Care Conference
Cytek Biosciences, Inc. (Nasdaq: CTKB) has announced its participation in the TD Cowen 46th Annual Health Care Conference, taking place in Boston, MA. The management team will engage in a hybrid presentation and fireside chat on March 4th, aimed at showcasing the company's advanced cell analysis solutions and technology. Interested attendees can access the event via a live and archived webcast through the company's investor relations website. Cytek is known for its innovative Full Spectrum Profiling technology, which enhances cell analysis capabilities.
Read more →CTKBCytek Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
Cytek Biosciences announced it will report its financial results for the fourth quarter and full year of 2025 on February 26, 2026. The company will hold a webcast conference call at 1:30 PM PT to discuss these results, along with business developments and future outlook. Cytek is known for its advanced cell analysis technologies, operating with a strong emphasis on high-resolution and high-sensitivity analysis through its proprietary Full Spectrum Profiling technology. The event will provide insights into the company's performance and strategic direction.
Read more →CTKB▲ +6.4%on this news
Cytek Biosciences Announces Preliminary Fourth Quarter and Full Year 2025 Revenue Results Company to present at the 44 th Annual JP Morgan Healthcare Conference
Cytek Biosciences, Inc. announced preliminary unaudited revenue results for 2025, expecting total revenue to reach approximately $201 million. The fourth quarter revenue is anticipated to be about $62 million, marking an 8% increase from the previous year. Positive trends include growth in services, reagents, and a return to positive revenue growth in EMEA, which the CEO regards as a sign of sustainable potential. However, the results are preliminary and subject to revision upon audit.
Read more →CTKBTIME Recognizes Cytek® Biosciences as One of America’s Growth Leaders of 2026
Cytek Biosciences has been named one of America's Growth Leaders of 2026 by TIME, highlighting its exceptional growth and financial stability over the past five years. The recognition underscores Cytek's commitment to innovation in high-parameter cell analysis solutions, which are crucial for advancing research in health and science. CEO Wenbin Jiang emphasized the company's mission to make cell analysis accessible and effective for all laboratories.
Read more →CTKBCytek® Muse® Micro Cell Analyzer Wins BioTech Breakthrough Award for Drug Discovery Solution of the Year
Cytek Biosciences' Muse Micro cell analyzer has been awarded Drug Discovery Solution of the Year at the 2025 BioTech Breakthrough Awards. This recognition emphasizes the system's affordability and ease of use, making sophisticated cell analysis accessible to smaller laboratories. The Muse Micro system builds on the legacy of the original Guava Muse system, enhancing flow cytometry capabilities.
Read more →CTKBCytek Biosciences to Participate in Upcoming Investor Conferences
Cytek Biosciences, Inc. has announced its participation in upcoming investor conferences, providing opportunities for stakeholders to access live and archived presentations. The company is recognized for its advanced cell analysis solutions, including its patented Full Spectrum Profiling technology. Cytek aims to enhance multiplexing precision and sensitivity in cell analysis.
Read more →CTKB▲ +13.2%on this newsshared move
Cytek Biosciences Reports Third Quarter 2025 Financial Results
Cytek Biosciences reported its financial results for Q3 2025, showing a 2% revenue increase to $52.3 million. Despite this growth, the company experienced a decrease in gross profit and an increase in operating expenses, leading to a net loss of $5.5 million. The CEO remains optimistic about the company's strategic priorities and long-term value delivery, reaffirming revenue guidance for the year.
Read more →CTKBCytek® Biosciences Deepens Commitment to Expanding Access to Flow Cytometry
Cytek Biosciences has launched a two-part initiative to enhance access to flow cytometry technology, addressing funding challenges in scientific research. The first phase includes awarding a three-laser flow cytometer, while the second phase will introduce a grant program for research projects. This effort aims to empower scientists in underserved regions and promote global public health.
Read more →CTKBCytek Biosciences to Report Third Quarter 2025 Financial Results on November 5, 2025
Cytek Biosciences, Inc. announced it will publish its financial results for Q3 2025 after market close on November 5, 2025. A conference call will follow to discuss the results alongside business developments and future outlook. The company is recognized for its advanced cell analysis solutions and patented Full Spectrum Profiling technology. Cytek highlights its operational transparency through various communication channels including webcasts and social media.
Read more →CTKBCytek® Biosciences Expands European Presence with New Facility in Amsterdam to Better Serve Customers and Drive Growth
Cytek Biosciences has relocated its European headquarters to a larger facility in Amsterdam's Life Sciences District. This expansion aims to enhance customer service and support for researchers, featuring a dedicated training center. The move reflects Cytek's commitment to the EMEA region and its strategic focus on improving operational efficiency and quality control in its reagent business.
Read more →CTKB▲ +10.4%on this news
Cytek Biosciences Brings Full Spectrum Cell Analysis to Leading Clinical Global Conferences ICCS and ESCCA
Cytek Biosciences will present its advanced Full Spectrum Profiling technology at two significant conferences: ESCCA 2025 in Montpellier, France, and ICCS 2025 in Philadelphia. These events will highlight the company's contributions to cancer research and diagnostics, featuring workshops on integrating spectral flow cytometry with machine learning for improved clinical decision-making.
Read more →CTKBCytek Biosciences Reports Second Quarter 2025 Financial Results
Cytek Biosciences reported its second-quarter financial results for 2025, highlighting a 2% decrease in revenue compared to the same quarter in 2024, primarily attributed to lower product sales in the EMEA and APAC regions. Despite these challenges, the company experienced growth in recurring revenue from services and launched the new Cytek Aurora Evo system. The loss from operations increased from $8.5 million to $10.6 million year-over-year, although the net loss improved from $10.4 million to $5.6 million. Cytek has narrowed its revenue guidance for the year, now projecting between $196 million and $205 million.
Read more →CTKBCytek Biosciences to Report Second Quarter 2025 Financial Results on August 6, 2025
Cytek Biosciences, Inc. (CTKB) has announced it will report its financial results for the second quarter of 2025 after market close on August 6, 2025. A corresponding conference call will be conducted beginning at 1:30 PM Pacific Time for management to discuss financial outcomes as well as business developments and future outlook. The event will be accessible to investors via a live webcast. Cytek emphasizes its advancements in high-resolution cell analysis through its Full Spectrum Profiling technology.
Read more →CTKBCytek Biosciences Is Setting the New Standard for Full Spectrum Flow Cytometry with the New Cytek Aurora™ Evo Flow Cytometer
Cytek Biosciences has launched the Cytek Aurora Evo flow cytometer, a next-generation system that improves on its predecessor, the Cytek Aurora. This new instrument enhances throughput and automation capabilities, addressing the modern research demands for efficient cell analysis tools. The Aurora Evo system incorporates advanced features for high-resolution detection of small particles, further establishing Cytek as a leader in spectral flow cytometry. The official unveiling will take place at CYTO 2025, where demonstrations are expected to showcase its capabilities.
Read more →CTKBCytek Biosciences to participate at the Goldman Sachs 46th Annual Global Healthcare Conference
Cytek Biosciences, Inc. (Nasdaq: CTKB) has announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference in Miami Beach, FL. Management is scheduled to present in a fireside chat on June 11th. The company focuses on delivering advanced cell analysis solutions through its patented Full Spectrum Profiling technology. Cytek also emphasizes that its products are primarily for research use, with specific clinical applications available in China and the EU.
Read more →CTKBCytek Biosciences Reports First Quarter 2025 Financial Results
Cytek Biosciences, Inc. reported its financial results for the first quarter of 2025, revealing a decrease in total revenue by 7.6% compared to the previous year. However, the company noted positive performance in key areas, particularly in its cell sorters and service sectors, alongside growth in the APAC region. The overall net loss increased to $11.4 million, reflective of rising operating expenses. Cytek has revised its full-year 2025 revenue guidance, forecasting growth of -2% to 5% over 2024.
Read more →CTKBCytek Biosciences Brings Cutting-Edge Cell Analysis Solutions to CYTO and IMMUNOLOGY2025
Cytek Biosciences is actively participating in prominent industry events, CYTO 2025 and IMMUNOLOGY2025, to showcase its patented Full Spectrum Profiling technology. This technology is designed to enhance workflows and foster scientific discoveries across immunology, oncology, and cell therapy. At the events, Cytek will offer demonstrations, workshops, and educational sessions to empower scientists with advanced cell analysis solutions. The initiative highlights Cytek's dedication to driving the next era of scientific advancement.
Read more →CTKBCytek Biosciences to Report First Quarter 2025 Financial Results on May 8, 2025
Cytek Biosciences, Inc. (CTKB) announced that it will report its first quarter 2025 financial results on May 8, 2025, after market close. A conference call is scheduled for the same day at 1:30 p.m. PT to discuss the results and future business developments. Cytek is known for its advanced cell analysis tools and technology, highlighting its focus on high-resolution and high-sensitivity analysis.
Read more →CTKBCytek Biosciences Expands Cell Analysis Offerings with the Affordable, User-Friendly Cytek Muse Micro System
Cytek Biosciences has announced the launch of the Cytek Muse Micro cell analyzer, a next-generation instrument designed to simplify flow cytometry at an affordable price. This system expands assay capabilities for various applications, including drug discovery and cell monitoring, and features an intuitive user interface. Built on the legacy of the original Muse system, the Muse Micro aims to make advanced cell analysis tools accessible to smaller labs and emerging markets. The system is already available for purchase, signaling a strategic move to broaden Cytek's market reach.
Read more →CTKBCytek Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Outlook
Cytek Biosciences reported its financial results for the fourth quarter and full year 2024, indicating a total revenue increase to $200.5 million for the year. The fourth quarter revenue saw a minor decrease of 1.3% year-over-year. Despite an operating loss of $20.5 million for 2024, the company highlighted growth in adjusted EBITDA and positive cash flow. Looking ahead, Cytek projects 2% to 6% revenue growth for 2025, signaling ongoing confidence in its market position and future profitability.
Read more →CTKBCytek Biosciences to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025
Cytek Biosciences, Inc. has announced it will release its financial results for the fourth quarter and full year of 2024 on February 27, 2025. The company will host a conference call to discuss these results, along with recent business developments and future outlook. This indicates that Cytek is maintaining transparency with stakeholders regarding its financial performance and strategic direction.
Read more →CTKB▼ -21.8%on this news
Cytek Biosciences Announces Preliminary Full Year 2024 Revenue Results
Cytek Biosciences has announced preliminary revenue results for the full year 2024, expecting earnings between $200 million and $201 million, reflecting a 4% growth year-over-year. Although the company faced challenges such as negative foreign exchange impacts and order delays, its fourth quarter revenue is expected to show significant growth when compared to earlier quarters. Cytek's performance particularly improved in the Asia Pacific and Rest of World markets, showcasing strong demand for its cell analysis tools. The company is scheduled to report comprehensive financial results and provide guidance for 2025 by late February 2025.
Read more →CTKBCytek Biosciences to present at the 43rd Annual J.P. Morgan Healthcare Conference
Cytek Biosciences, Inc. (Nasdaq: CTKB) announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference scheduled for January 16th, 2025. The company is anticipated to present at 8:15 a.m. PT, which will be accessible via a live and archived webcast on its investor relations website. Cytek is acknowledged for advancing cell analysis solutions with its patented Full Spectrum Profiling technology, enhancing the precision and sensitivity of cell analysis.
Read more →CTKBCytek Biosciences Announces $50 Million Stock Repurchase Program for 2025
Cytek Biosciences, Inc. has announced a $50 million stock repurchase program approved by its Board of Directors, set to commence on January 1, 2025. This program will replace the existing stock buyback that expires on December 31, 2024. The repurchases will be carried out in the open market or through negotiated transactions. The decision reflects the company's confidence in its financial standing and the intention to enhance shareholder value.
Read more →CTKBCytek Biosciences to participate in the Piper Sandler 36th Annual Healthcare Conference
Cytek Biosciences, a cell analysis solutions company, announced its participation in the Piper Sandler 36th Annual Healthcare Conference, scheduled for December 3, 2024. The management will take part in a fireside chat at 4:30 p.m. Eastern Time. Interested parties can access the live and archived webcast through the company's website. This engagement is expected to boost investor interest and promote the company's innovative products.
Read more →CTKBCytek Biosciences Named “Overall BioTech Company of the Year” in 2024 BioTech Breakthrough Awards Program
Cytek Biosciences has been awarded 'Overall BioTech Company of the Year' in the 2024 BioTech Breakthrough Awards program, recognized for its innovation in spectral flow cytometry. The award highlights the company's role in advancing cell analysis tools, which are crucial for research in immunology and oncology. Cytek is noted for its initiative to make flow cytometry technology more accessible, thereby facilitating significant advancements in scientific research. This recognition adds to the company's credibility as a leader in biotechnology.
Read more →CTKBCytek Biosciences Becomes First Company to Add Ability to Detect Subcellular Particles to Its Cell Sorter
Cytek Biosciences has launched the Enhanced Small Particle (ESP™) Detection Option for its Cytek Aurora™ CS system, making it the first commercial small particle detector on a cell sorter. This innovation allows researchers to analyze small particles as small as 70 nm, significantly enhancing capabilities in various biomedical fields like drug delivery and disease diagnostics. The new feature is expected to open up new research and commercial opportunities for Cytek, solidifying its position in the growing area of exosome and extracellular vesicle research.
Read more →CTKBCytek Biosciences Reports Third Quarter 2024 Financial Results
Cytek Biosciences reported its financial results for the third quarter of 2024, highlighting a 7% increase in total revenue year-over-year, amounting to $51.5 million. Despite continuing industry headwinds, the company's net income reached $0.9 million, a significant improvement over a net loss in the previous year. Cytek also reaffirmed its full year revenue guidance of $203 million to $210 million, indicating expected growth of 5% to 9% from 2023. While expenses slightly decreased, the company reported a loss from operations of $4.2 million for the quarter.
Read more →CTKBCytek Biosciences to Report Third Quarter 2024 Financial Results on November 5, 2024
Cytek Biosciences, Inc. (NASDAQ: CTKB) announced it will report its financial results for the third quarter of 2024 on November 5, 2024. Following the report, the company will host a conference call to discuss the results and provide insights into its business developments and outlook. This call will stream live and is part of Cytek's strategy to keep investors informed about its operations and financial performance. The company emphasizes its advanced cell analysis tools and technologies, underscoring its industry position.
Read more →CTKB▼ -5.2%on this news
Cytek Biosciences Brings Full Spectrum Profiling™ (FSP™) Technology to the Forefront at Major Clinical Conferences in the U.S. and Europe
Cytek Biosciences is set to highlight its Full Spectrum Profiling (FSP) technology at two important clinical conferences in Europe and the U.S. The company intends to enhance lab productivity and result accuracy through its innovative solutions. The ESCCA 2024 Conference will feature a symposium focused on advanced techniques for AML-MRD analysis, while the ICCS Meeting will foster collaboration and education on clinical cytometry. Notable presentations by industry experts will underpin the significance of Cytek's technology in improving health diagnostics.
Read more →CTKB▼ -13.7%on this news
Cytek Announces Resignation of Chief Operating Officer Chris Williams
Cytek Biosciences, Inc. announced the resignation of its Chief Operating Officer, Chris Williams, effective September 27, 2024, as he will take on a CEO role at another company. Rather than filling the COO position, Cytek plans to restructure its management to improve efficiency. Williams has been a key figure in the company's growth and operational enhancements, and his departure will mark a new phase for Cytek as it seeks to streamline its organization. The transition is expected to bolster Cytek’s agility and empower its teams for future success.
Read more →CTKBCytek Biosciences Achieves ISO 13485 Certification at San Diego Reagent Manufacturing Facility
Cytek Biosciences has announced that its San Diego reagent manufacturing facility received EN ISO 13485:2016 certification, reflecting the company's commitment to high quality management standards. This certification supports compliance with international regulations and aims to enhance patient safety in healthcare delivery. It also positions Cytek favorably for expanding its offerings into the U.S. clinical market. The certification was awarded following a rigorous assessment by TüV Rheinland.
Read more →CTKBCytek Biosciences Reports Second Quarter 2024 Financial Results
Cytek Biosciences reported its financial results for Q2 2024, highlighting a 6% decrease in total revenue to $46.6 million compared to Q2 2023. This decline was primarily attributed to reduced U.S. instrument sales, although the company achieved strong revenue growth in EMEA and APAC regions. Despite facing challenges in the domestic market, Cytek remains optimistic about its long-term growth potential and has adjusted its 2024 revenue guidance to a range of $203 million to $210 million, indicating an expected growth of 5% to 9% from the prior year.
Read more →CTKBCytek Biosciences Automates Panel Design with New Intelligent Algorithm
Cytek Biosciences has introduced the SpectroPanel tool, an intelligent algorithm designed to automate and optimize panel design within its Cytek Cloud platform. This innovation streamlines the labor-intensive process of assigning fluorochromes to markers, allowing researchers to complete this task significantly faster than before. With the tool's capabilities tailored for Cytek's Full Spectrum Profiling technology, it is anticipated to facilitate broader adoption of flow cytometry technologies in various research fields. The company also plans to further expand the functionalities of Cytek Cloud to enhance data management and analysis features.
Read more →CTKBCytek Biosciences to Report Second Quarter 2024 Financial Results on August 6, 2024
Cytek Biosciences, Inc. announced it will report its second quarter financial results for 2024 after the market closes on August 6, 2024. The management will accompany this announcement with a conference call to discuss the results and the company's future outlook. Cytek is known for its high-resolution cell analysis solutions and patented Full Spectrum Profiling technology.
Read more →CTKBCytek Biosciences Announces $50 Million Stock Repurchase Program
Cytek Biosciences, Inc. announced the approval of a $50 million stock repurchase program by its Board of Directors. This initiative allows the company to buy back its common stock in the open market or through privately negotiated transactions until December 31, 2024. The decision emphasizes the company’s confidence in its current financial status and operational prospects. However, the program remains flexible, meaning it can be modified or suspended at the discretion of the Board based on various factors, like market conditions.
Read more →CTKBCytek Biosciences to participate at the Goldman Sachs 45th Annual Global Healthcare Conference
Cytek Biosciences, Inc. announced its participation in the Goldman Sachs 45th Annual Global Healthcare Conference in Miami Beach, Florida. The company's management will take part in a fireside chat scheduled for June 12th, which will be accessible via a live and archived webcast on their website. This event highlights Cytek's active role in the healthcare sector and its commitment to investor relations, emphasizing its advanced cell analysis solutions.
Read more →CTKBCytek Biosciences Adds Ability to Detect Subcellular Particles to Its Industry-Leading Cell Analysis Systems
Cytek Biosciences, Inc. has announced the release of its Enhanced Small Particle (ESP™) Detection Option for the Cytek Aurora™ and Cytek Northern Lights™ cell analysis systems. This upgrade significantly improves sensitivity and resolution, allowing for the detection of subcellular particles as small as 70 nm, such as extracellular vesicles. The company aims to capitalize on a growing market for small particle research, predicted to increase substantially by 2028. This development is expected to enhance the capabilities of researchers working in areas such as biomarker development and therapeutic applications.
Read more →CTKBCytek Biosciences Reports First Quarter 2024 Financial Results
Cytek Biosciences reported strong financial performance for the first quarter of 2024, with revenues of $44.9 million, which is a 21% increase year-over-year. The company's organic revenue growth also saw an 11% rise, driven by improved customer spending and an expanded services business. Despite experiencing a decline in gross profit margin and an operating loss, the company maintains a strong cash position and has affirmed its revenue guidance for the full year. Cytek aims for overall revenue growth of 5% to 10% for 2024 and expects to achieve positive net income by year-end.
Read more →CTKBCytek Biosciences to Spotlight Cell Analysis Solutions at Upcoming Conferences in the United States and Europe
Cytek Biosciences will participate in CYTO 2024 and AAI’s IMMUNOLOGY2024 conferences, showcasing its Full Spectrum Profiling technology. This innovative approach aims to enhance efficiency in cell analysis workflows. Key personnel from Cytek will conduct workshops and presentations to highlight advancements in the understanding of the immune system and cellular analysis methodologies. These events underline Cytek's commitment to empowering researchers with advanced tools for scientific discovery.
Read more →CTKBCytek Biosciences to Report First Quarter 2024 Financial Results on May 8, 2024
Cytek Biosciences, Inc. (Nasdaq: CTKB) announced it will report its financial results for the first quarter of 2024 on May 8, 2024. The announcement includes a webcast scheduled for 1:30 p.m. Pacific Time, where management will discuss the results and business updates. The company is known for its proprietary Full Spectrum Profiling technology, which enhances cell analysis capabilities across various platforms. This presentation will be accessible via their investor website.
Read more →CTKBCytek Biosciences Names William McCombe Chief Financial Officer Experienced executive with extensive background as CFO for global corporations across dynamic sectors Cytek reaffirms 2024 outlook
Cytek Biosciences has appointed William McCombe as its new Chief Financial Officer, effective immediately. McCombe brings over 20 years of experience in financial management from prominent roles in various technology companies. Under his leadership, Cytek aims to achieve a revenue growth of 5% to 10% in 2024 and expects to maintain positive net income. The company has also reaffirmed its outlook for the year ahead.
Read more →CTKBCytek Biosciences Opens New Facility to Address Increasing Global Demand for Cutting-Edge Cell Analysis Solutions
Cytek Biosciences, Inc. has opened a new 50,000-square-foot facility in Wuxi, China, to enhance its manufacturing capacity in response to increasing global demand for cell analysis solutions. This strategic development will support various operations including research and development, sales, and marketing. Cytek is known for its innovative flow cytometry platforms, particularly the Cytek Aurora CS system, which offers cutting-edge performance through its Full Spectrum Profiling technology. The company aims to continue expanding its global footprint while providing advanced tools for scientific research.
Read more →CTKBCytek Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Outlook
Cytek Biosciences reported its financial results for the fourth quarter and full year of 2023, showcasing a 21% increase in fourth quarter revenue compared to the previous year. The company is optimistic about its growth prospects, expecting revenue to reach between $203 million and $213 million in 2024. However, increased operating expenses and a decline in gross profit margin were noted as concerns. Cytek's CEO emphasized the company's focus on strategic growth and delivering long-term profitability.
Read more →CTKBCytek Biosciences to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
Cytek Biosciences, Inc. (Nasdaq: CTKB) announced that it will report its financial results for the fourth quarter and full year of 2023 on February 28, 2024. A conference call will follow the release to discuss the results, business developments, and outlook. The company is recognized for its Full Spectrum Profiling technology, which enhances cell analysis capabilities. Investors can access the live webcast through the company's investor relations website.
Read more →CTKBCytek Biosciences Signs Agreement with CRG and UPF to Accelerate Scientific Discoveries
Cytek Biosciences has entered into a collaborative agreement with the Centre for Genomic Regulation and Pompeu Fabra University to advance technological innovation in cell analysis. This partnership will allow Cytek to provide advanced spectral cytometry platforms and trained personnel to the CRG-UPF Flow Cytometry Unit, facilitating improved research capabilities. The collaboration aims to enhance the scientific community's ability to conduct high-resolution cell analysis, potentially leading to significant advancements in various biomedical fields.
Read more →CTKB▲ +10.3%on this news
Cytek Biosciences Announces Preliminary Full Year 2023 Revenue Results
Cytek Biosciences has announced preliminary unaudited revenue results for the full year 2023, anticipating revenues to be between $188 million and $192 million. This is at the high end of their previously provided revenue guidance. The company plans to formally report its financial results for Q4 and the full year at the end of February 2024. Cytek is actively participating in the 42nd Annual J.P. Morgan Healthcare Conference, showcasing its advancements in cell analysis technology.
Read more →CTKBCytek Biosciences to present at the 42nd Annual J.P. Morgan Healthcare Conference
Cytek Biosciences, Inc. (Nasdaq: CTKB) has announced its participation in the 42nd Annual J.P. Morgan Healthcare Conference, set to take place in San Francisco, CA. CEO Dr. Wenbin Jiang is scheduled to present and answer questions on January 11 at 8:15 a.m. PT. This event showcases Cytek's advancements in cell analysis technologies, notably their patented Full Spectrum Profiling (FSP) technology, which enhances cell analysis precision and multiplexing capabilities.
Read more →CTKBCytek Biosciences Introduces the Cytek Orion™ Reagent Cocktail Preparation System, the First-of-its-Kind Automated Cocktail Preparation Instrument for Flow Cytometry
Cytek Biosciences has launched the Cytek Orion™ reagent cocktail preparation system, an innovative automated instrument aimed at enhancing laboratory efficiency in flow cytometry. This system simplifies the preparation of multicolor antibody cocktails by allowing users to mix up to 60 individual reagents, significantly reducing the risk of human error. The product's design integrates well with Cytek's existing ecosystem and focuses solely on cocktail preparation, positioning it effectively for applications such as drug discovery. Cytek's CEO highlighted the cost-effectiveness of the Orion, which is priced competitively compared to existing solutions.
Read more →CTKBSafe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding Cytek's business and o
Cytek Biosciences recently presented forward-looking statements regarding its business strategies and market opportunities following the acquisition of Luminex's flow cytometry and imaging business. The company highlighted its strong financial position and broad customer base, which includes over 1,500 clients across more than 70 countries. Cytek's leadership aims to leverage these resources to enhance its technological capabilities and operational efficiencies. The presentation also emphasized the strategic benefits of the acquisition, including access to operational synergies and expected growth in clinical applications.
Read more →CTKB▲ +10.3%on this news· ran to +21% by day 3
Cytek Biosciences to participate in the Piper Sandler 35th Annual Healthcare Conference
Cytek Biosciences, Inc. (Nasdaq: CTKB) announced its participation in the Piper Sandler 35th Annual Healthcare Conference scheduled for November 28th, 2023. During the event, Cytek management will host a fireside chat accessible via a live and archived webcast. The company, known for its advanced cell analysis solutions, continues to highlight its innovative Full Spectrum Profiling technology during investor engagements.
Read more →CTKBQ3 2023 Earnings Call Event Details Date: 2023-11-07 Company: Cytek Biosciences, Inc. Ticker: CTKB-US Company Participants Paul Goodson - Cytek Biosciences, Inc., Head-Investor Relations Wenbin Jiang - Cytek Biosciences,
Cytek Biosciences, Inc. announced its Q3 2023 earnings, reporting a total revenue of $48.0 million, which is a 19% increase from the previous year. Despite this growth, the company noted challenges such as extended sales cycles and delays in orders, which may affect performance in the upcoming quarter. They project that full-year organic revenue will remain flat, although revenues from their recent acquisition are expected to contribute significantly. The upcoming launch of the Cytek Orion smart cocktail reagent mixer is aimed at enhancing laboratory efficiencies, showcasing the company's commitment to innovation.
Read more →CTKB▲ +12.4%on this newsshared move
Cytek Aurora™ CS System Wins BioTech Breakthrough Award for ‘Cell Sorting Product of the Year’
Cytek Biosciences, Inc. has announced that its Cytek® Aurora™ CS system received the 'Cell Sorting Product of the Year' award in the BioTech Breakthrough Awards program. This recognition showcases the system's advanced technology, specifically its Full Spectrum Profiling™ capability, which improves the sorting of complex cell populations. The award reflects the competitive edge Cytek holds in the cell analysis solutions market amidst over 1,500 nominations from 12 countries. Cytek's commitment to continuous innovation positions them for future advancements in life sciences research.
Read more →CTKBCytek Biosciences Reports Third Quarter 2023 Financial Results
Cytek Biosciences has reported its financial results for Q3 2023, indicating total revenues of $48 million, a 19% year-over-year growth. The company acknowledges ongoing macroeconomic pressures but emphasizes its commitment to operational efficiency and maintaining profitability. A significant portion of revenue came from products acquired from Luminex, while organic revenue saw a modest increase of 2%. Despite these positives, the gross profit margin has decreased significantly, and the company is reporting operational losses this quarter.
Read more →CTKBCytek Biosciences to Report Third Quarter 2023 Financial Results on November 7, 2023
Cytek Biosciences, Inc. will report its third quarter financial results for 2023 on November 7, 2023, after market close. The company will hold a conference call at 1:30 p.m. Pacific Time to discuss its results and future outlook. Cytek is recognized for its advanced cell analysis solutions, including its Full Spectrum Profiling technology, and maintains a global presence in the market. The webcast will be accessible via the company's Investors section on its website.
Read more →CTKBCytek Biosciences Achieves ISO 13485 Certification at Headquarters
Cytek Biosciences, Inc. announced that it has received EN ISO 13485:2016 Quality Management System certification for its headquarters and manufacturing operations in Fremont, California. This certification underscores the company's commitment to regulatory compliance and quality in the design and manufacturing of flow cytometers and related products. The company aims to build on this achievement to expand its offerings in the clinical market, particularly targeting the U.S. Cytek's innovative Full Spectrum Profiling technology plays a crucial role in advancing cell analysis solutions for researchers globally.
Read more →CTKBCytek Biosciences Cell Analysis Solutions Take Center Stage at Upcoming Clinical Conferences in the US and Europe
Cytek Biosciences, Inc. (Nasdaq: CTKB), a leader in cell analysis solutions, is set to showcase its Full Spectrum Profiling technology at key clinical conferences in Europe and the US. Attending the ESCCA 2023 in the Netherlands and ICCS Annual Meeting & Course in New Orleans, Cytek aims to enhance awareness and familiarity with its innovative solutions among professionals. Dr. Manuel Ramirez will lead a symposium discussing optimizing B cell panels for childhood B-ALL at ESCCA. At ICCS, Cytek will highlight the importance of assay optimization and panel design in laboratory tests.
Read more →CTKBCytek Biosciences to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference
Cytek Biosciences, Inc. (Nasdaq: CTKB) has announced its participation in the 2023 Cantor Fitzgerald Global Healthcare Conference set for September 27th in New York. The company's management will engage in a fireside chat, which will be accessible via a live and archived webcast on their investor relations page. Cytek is recognized for its innovative cell analysis solutions and will highlight its advanced technology, including Full Spectrum Profiling, during the conference.
Read more →CTKBCytek Biosciences Launches Educational Roadshow Focused on Spectral Flow Cytometry
Cytek Biosciences, Inc. has announced the launch of its global educational roadshow, Cytek Reveal, aimed at enhancing understanding of spectral flow cytometry. The roadshow will commence in South San Francisco on October 5, 2023, and will include several major cities in the U.S. and the U.K. Participants will benefit from in-depth presentations on the applications and advantages of Cytek's Full Spectrum Profiling technology, emphasizing its importance in cell analysis. The initiative aims to establish Cytek as a leader in the life sciences community, focusing on user-friendly tools that streamline complex research processes.
Read more →CTKBCytek Biosciences to participate in the Morgan Stanley 21st Annual Global Healthcare Conference
Cytek Biosciences, Inc. announced its participation in the Morgan Stanley 21st Annual Global Healthcare Conference, which is set to take place in New York. Management will engage in a fireside chat on September 13th, providing insights into the company's innovative cell analysis solutions. Investors can access the live and archived webcast through the company’s website. Cytek's products are primarily for research use, with some available for clinical use in certain regions.
Read more →CTKBCytek Biosciences Appoints Dr. Philippe Busque Senior Vice President of Global Sales & Services
Cytek Biosciences has appointed Dr. Philippe Busque as Senior Vice President of Global Sales & Services. This strategic move aims to enhance the company's sales organization by integrating multiple sales teams and focusing on a market-driven approach. The restructure follows Cytek's acquisition of the Amnis and Guava brands and comes as the company seeks to expand its capabilities in cell analysis solutions. Dr. Busque brings extensive experience from previous roles in the life science sector and is expected to lead efforts in developing customer engagement and product offerings.
Read more →CTKBCytek Biosciences to Participate in the UBS MedTech, Tools and Genomics Summit
Cytek Biosciences, Inc. (Nasdaq: CTKB) announced its participation in the 2023 UBS MedTech, Tools and Genomics Summit in Dana Point, CA. Scheduled for August 16, Cytek management will join a panel discussing Emerging Life Science Technologies Across Genomics and Proteomics. Additionally, they will hold one-on-one meetings with investors on August 16 and 17. This participation underscores Cytek's commitment to advancing its role in cell analysis solutions and engaging with the investment community.
Read more →CTKBCytek Biosciences Reports Second Quarter 2023 Financial Results
Cytek Biosciences reported its financial results for Q2 2023, showing a 24% increase in revenue to $49.7 million, boosted by the integration of Luminex's product lines. However, despite the growth in revenue, the company faced challenges with a significant increase in operating expenses and a larger net loss compared to the same quarter last year. Cytek is optimistic about its future, projecting total revenue growth of 25%-34% for the year. The company also emphasized ongoing momentum in its product development and market presence.
Read more →CTKBCytek Biosciences to Report Second Quarter 2023 Financial Results on August 8, 2023
Cytek Biosciences, Inc. is set to report its second quarter 2023 financial results on August 8, 2023, after market close. A conference call will be held at 1:30 p.m. Pacific Time to discuss the results and the company’s business developments. Cytek continues to position itself as a leader in the cell analysis field through its advanced Full Spectrum Profiling technology.
Read more →CTKBCytek Biosciences to Participate in the 44th Annual Goldman Sachs Healthcare Conference
Cytek Biosciences, Inc. (Nasdaq: CTKB) has announced its participation in the 44th Annual Goldman Sachs Healthcare Conference scheduled for June 14th. The company's management will engage in a fireside chat, which will be accessible via a live and archived webcast. This event presents an opportunity for Cytek to showcase its innovations in cell analysis solutions and reach a wider audience in the healthcare investment community.
Read more →CTKB▼ -5.4%on this newsshared move
Cytek Biosciences Marks Shipment of Its 100th Cell Sorter as the Company Continues to Lead Cell Analysis Forward
Cytek Biosciences announced the shipment of its 100th Cytek Aurora CS system, highlighting the growing demand for its Full Spectrum Profiling (FSP) technology. This achievement underscores the company’s momentum and commitment to advancing cell analysis solutions. Following a recent acquisition of Luminex's flow cytometry and imaging business, Cytek continues to expand its offerings and capabilities in the market. The company's success is further demonstrated by over 1,150 peer-reviewed publications citing its products in various research fields.
Read more →CTKBCytek Biosciences Reports First Quarter 2023 Financial Results
Cytek Biosciences reported its financial results for Q1 2023, showing a total revenue of $37.1 million, driven partially by its recent acquisition of Luminex's product lines. Despite experiencing a growth in revenue overseas, particularly in Europe and APAC, the company faced a decline in organic revenue, mainly attributed to softness in the U.S. pharma and biotech markets. The company projected a revised revenue outlook for the full year, dampened by macroeconomic uncertainties affecting sales cycles. Overall, the financial performance was mixed, highlighting both growth opportunities and challenges.
Read more →CTKBCytek Biosciences to Report First Quarter 2023 Financial Results on May 9, 2023
Cytek Biosciences, Inc. has announced that it will report its financial results for the first quarter of 2023 on May 9, 2023. Following the announcement, the management team will lead a conference call at 1:30 p.m. PT to discuss financial performance, business developments, and the company's outlook. Cytek has been actively expanding its cell analysis solutions with notable acquisitions, including the addition of imaging flow cytometers to its product lineup.
Read more →CTKBCytek Biosciences Introduces New 20-Color AML Panel
Cytek Biosciences has launched a new 20-Color Acute Myeloid Leukemia (AML) Panel, a single-tube flow cytometry assay designed to streamline AML analysis. This innovative assay is expected to enhance researchers' efficiency by reducing the need for redundant reagents and saving time during sample preparation. The new panel leverages Cytek's Full Spectrum Profiling technology, allowing for more comprehensive cellular data and improved assay sensitivity. This launch aims to facilitate the development of effective therapies for AML.
Read more →CTKBCytek Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results 2022 revenue increased 32%, and 34% on constant currency basis, compared to prior year Expects full year 2023 revenue of $225 million to $235
Cytek Biosciences reported strong financial performance for the fourth quarter and full year 2022, with revenue growth of 32% year-over-year. The company indicates a positive outlook for 2023 with expected revenue ranging between $225 million and $235 million, bolstered by the recent acquisition of Luminex's Flow Cytometry and Imaging business. However, operating expenses saw a significant rise, impacting profitability despite overall improved financial results.
Read more →CTKBC YTEK B IOSCIENCES TO A CQUIRE F LOW C YTOMETRY AND I MAGING B USINESS FROM D IA S ORIN S ALE OF ASSETS RELATED TO F LOW C YTOMETRY & I MAGING (FCI) B USINESS U NIT A CQUISITION WILL EXPAND C YTEK S PRODUCT PORTFOLIO TO
Cytek Biosciences has entered into an agreement to acquire the Flow Cytometry & Imaging (FCI) business unit from DiaSorin's subsidiary Luminex Corporation. The deal, expected to close within 30 days, will introduce extensive resources, including over 7,000 instruments, to Cytek's portfolio. The acquisition aligns with DiaSorin's strategy to focus on its core capabilities while enhancing Cytek's presence in cellular research. This strategic move is anticipated to strengthen Cytek's market offerings and broaden its reach in under-served customer segments.
Read more →CTKBCytek Biosciences to Acquire Flow Cytometry and Imaging Business from DiaSorin
Cytek Biosciences has announced the acquisition of the Flow Cytometry & Imaging (FCI) business from DiaSorin's subsidiary, Luminex Corporation. This strategic move is designed to enhance Cytek's offerings by integrating advanced imaging flow cytometry solutions and increasing its global footprint through an existing base of 7,000 instruments. The transaction is anticipated to close within 30 days, following customary conditions. Additionally, more than 60% of the FCI business's employees will join Cytek, which promises to strengthen its commercial capabilities.
Read more →CTKBCytek Biosciences to Report Fourth Quarter and Full Year 2022 Financial Results on February 28, 2023
Cytek Biosciences, Inc. has announced that it will report its financial results for the fourth quarter and full year of 2022 on February 28, 2023, after market close. The company will also hold a webcast conference call to discuss these results, business developments, and future outlook. This provides an opportunity for investors to gain insights into the company's performance and strategic direction.
Read more →CTKBCytek Biosciences Partners with Bio-Rad to Expand Reagent Portfolios
Cytek Biosciences has entered into a strategic partnership with Bio-Rad to enhance its reagent portfolio for immuno-oncology research. This collaboration will allow Cytek to utilize Bio-Rad's StarBright Dyes, enabling the development of high-parameter applications for their Aurora and Northern Lights flow cytometry systems. The integration of these advanced dyes aims to improve the resolution of cell populations and facilitate multiparameter analysis. With this partnership, Cytek aims to provide researchers with more options and streamline the process of panel design for scientific studies.
Read more →CTKBCytek Biosciences to Participate in the Piper Sandler Healthcare Conference
FREMONT, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced the company will be participating in the upcoming Piper Sandler Healthcare Conference in New York, NY. Cytek management is scheduled to par
Read more →CTKBCytek Biosciences Introduces Cytek Cloud
FREMONT, Calif., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced the launch of Cytek Cloud – a cloud-based platform that features two integrated tools to streamline workflows on Cytek’s state-of-the-art cell sorters and analyzers. Optimize
Read more →CTKB▼ -5.6%on this news
Cytek Biosciences Reports Third Quarter 2022 Financial Results Third quarter revenue grew 18% compared to prior year quarter Improved gross margins, net income, and adjusted EBITDA over prior year quarter
Cytek Biosciences Reports Third Quarter 2022 Financial Results Third quarter revenue grew 18% compared to prior year quarter Improved gross margins, net income, and adjusted EBITDA over prior year quarter FREMONT, Calif., November 9, 2022 (GLOBE NEWSWIRE) Cytek Biosciences, I
Read more →CTKBCytek Biosciences Names Chris Williams Chief Operating Officer Experienced Biotech, Pharmaceutical Industry Leader to Guide Operations Growth and Scalability
Cytek Biosciences Names Chris Williams Chief Experienced Biotech, Pharmaceutical Industry Leader to Guide Operations Growth and Scalability FREMONT, Calif., October 31, 2022 Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced that Chris Williams has been appointed chief ope
Read more →CTKBCytek to Participate in the 31st Annual Credit Suisse Healthcare Conference
FREMONT, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced the company will be participating in the upcoming 31st Annual Credit Suisse Healthcare Conference in Rancho Palos Verdes, CA. Cytek’s manag
Read more →CTKBCytek Biosciences to Report Third Quarter 2022 Financial Results on November 9, 2022
FREMONT, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the third quarter 2022 after market close on Wednesday, November 9th, 2022. The company’s management wi
Read more →CTKBCytek to Participate in the 20th Annual Morgan Stanley Global Healthcare Conference
FREMONT, Calif., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced the company will be participating in the upcoming 20th Annual Morgan Stanley Global Healthcare Conference in New York, NY. Cytek’s manageme
Read more →CTKB▲ +5.2%on this news
Cytek Biosciences Reports Second Quarter 2022 Financial Results Second quarter revenue grew 32% compared to prior year
Cytek Biosciences Reports Second Quarter 2022 Financial Results Second quarter revenue grew 32% compared to prior year FREMONT, Calif., August 10, 2022 (GLOBE NEWSWIRE) Cytek Biosciences, Inc. ( Cytek Biosciences or Cytek ) (Nasdaq: CTKB) today reported financial results for t
Read more →CTKBCytek to Participate in the 42nd Annual Canaccord Genuity Global Growth Conference
FREMONT, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced the company will be participating in the upcoming 42nd Annual Canaccord Genuity Global Growth Conference in Boston, MA. Cytek’s management
Read more →CTKBCytek Biosciences to Report Second Quarter 2022 Financial Results on August 10, 2022
FREMONT, Calif., July 20, 2022 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the second quarter 2022 after market close on Wednesday, August 10th, 2022. The company’s management wi
Read more →CTKBCytek Biosciences to Host Inaugural Analyst and Investor Day
FREMONT, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB) announced today that it will host its inaugural Analyst and Investor Day on Wednesday June 22, with presentations beginning at 9:00 a.m. ET. At this event,
Read more →CTKBCytek Biosciences Receives CE Marking for Series of cFluor Reagents, TBNK Kit
FREMONT, Calif., May 24, 2022 (GLOBE NEWSWIRE) -- Clinical flow cytometry laboratories based in Europe can now purchase Cytek cFluor® CE-IVD-certified reagents for their use. Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced that a
Read more →CTKB▼ -7.8%on this news· ran to +23% by day 3
Cytek Biosciences Reports First Quarter 2022 Financial Results First quarter revenue grew 44% compared to prior year
Cytek Biosciences Reports First Quarter 2022 Financial Results First quarter revenue grew 44% compared to prior year FREMONT, Calif., May 11, 2022 (GLOBE NEWSWIRE) Cytek Biosciences, Inc. ( Cytek Biosciences or Cytek ) (Nasdaq: CTKB) today reported financial results for the fi
Read more →CTKB▲ +5.3%on this news
Cytek Biosciences to Report First Quarter Financial Results on May 11, 2022
FREMONT, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the first quarter 2022 after market close on Wednesday, May 11th, 2022. The company’s management will
Read more →CTKB▲ +5.3%on this news
Cytek Biosciences Appoints Todd Garland Chief Commercial Officer
FREMONT, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the appointment of Todd Garland as Chief Commercial Officer, Cytek Biosciences, Inc. Garland’s appointment is effective immediate
Read more →CTKBCytek Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results 2021 Revenue Increased 38% Compared to Prior Year
Cytek Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results 2021 Revenue Increased 38% Compared to Prior Year FREMONT, Calif., Feb. 23, 2022 (GLOBE NEWSWIRE) Cytek Biosciences, Inc. ( Cytek Biosciences or Cytek ) (Nasdaq: CTKB) today reported financial result
Read more →CTKBCytek to Participate in the 42nd Annual Cowen Health Care Conference
FREMONT, Calif., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced the company will be participating virtually in the upcoming 42nd Annual Cowen Health Care Conference. Cytek’s management is scheduled to pa
Read more →CTKBCytek Biosciences to Report Fourth Quarter and Full Year 2021 Financial Results on February 23, 2022
FREMONT, Calif., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the fourth quarter and full year 2021 after market close on Wednesday, February 23rd, 2022. The company
Read more →CTKBCytek Biosciences Expands Fremont Headquarters, Tripling Its Manufacturing Capacity
FREMONT, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced that it has opened a new facility in Fremont, California – tripling its current manufacturing capacity in order to meet growing gl
Read more →CTKBCytek Biosciences Marks Milestone Achievement with Shipment of 1000th Cell Analysis System
FREMONT, Calif., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced a significant milestone: the company has shipped 1,000 of its cell analysis systems. Since first being introduced in 2017, Cytek’s
Read more →CTKBCytek Biosciences Reports Third Quarter 2021 Financial Results Third quarter total revenue growth of 37% compared to prior year
Cytek Biosciences Reports Third Quarter 2021 Financial Results Third quarter total revenue growth of 37% compared to prior year FREMONT, Calif., Nov. 8, 2021 (GLOBE NEWSWIRE) Cytek Biosciences, Inc. ( Cytek Biosciences or Cytek ) (Nasdaq: CTKB) today reported financial results
Read more →CTKBCytek Biosciences Acquires Tonbo Biosciences’ Cell Analysis Business
FREMONT, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced that it has acquired the cell analysis business of Tonbo Biosciences™, which includes an extensive portfolio of life science rese
Read more →CTKBCytek Biosciences to Report Third Quarter Financial Results on November 8, 2021
FREMONT, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the third quarter 2021 after market close on Monday, November 8th, 2021. The company’s management will
Read more →CTKBCytek Biosciences Introduces New 25-Color Immunoprofiling Assay
FREMONT, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- The field of medical research has a new tool to develop vaccines, personal immunotherapies, and cures for cancer and other infectious diseases using Full Spectrum Profiling™ (FSP™) technology. Cytek Biosciences, Inc. (Nasdaq: CTK
Read more →CTKB▲ +17%on this news
Cytek Biosciences to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
FREMONT, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB) today announced the company will be participating in the Morgan Stanley 19th Annual Global Healthcare Conference. Cytek’s management is scheduled to presen
Read more →CTKB▲ +17%on this news
Cytek Biosciences Reports Second Quarter 2021 Financial Results
Cytek Biosciences Reports Second Quarter 2021 Financial Results FREMONT, Calif., Sept. 2, 2021 (GLOBE NEWSWIRE) Cytek Biosciences, Inc. ( Cytek Biosciences or Cytek ) (Nasdaq: CTKB) today reported financial results for the second quarter ended June 30, 2021. During the quarter
Read more →CTKB▲ +7.8%on this news· ran to +20% by day 1
Cytek Biosciences Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
FREMONT, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, announced today that the underwriters of its previously announced initial public offering, which closed on July 2
Read more →CTKBCytek Biosciences Announces Closing of Its Initial Public Offering
FREMONT, Calif., July 27, 2021 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, announced today the closing of its initial public offering of an aggregate of 14,564,635 shares of its common sto
Read more →CTKBCytek Biosciences Announces Pricing of Its Initial Public Offering
FREMONT, Calif., July 22, 2021 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, announced today the pricing of its initial public offering of an aggregate of 16,749,330 shares of its common sto
Read more →CTKBCytek Biosciences Introduces a New High-Dimensional Sorter
FREMONT, Calif., June 07, 2021 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc., a leading cell analysis solutions company, today introduced a new high-dimensional benchtop cell sorter – the Cytek Aurora CS. Built on the same Full Spectrum Profiling™ (FSP™) technology comprising Cytek
Read more →CTKBCytek Biosciences Appoints Allen Poirson as Senior Vice President of Marketing and Corporate Development
FREMONT, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc., a leading life sciences technology company, today announced that Allen Poirson, Ph.D. has been appointed as the senior vice president of marketing and corporate development for the company. In this role,
Read more →CTKBCytek Biosciences Debuts Optimized Immunoprofiling Kit
FREMONT, Calif., Dec. 15, 2020 (GLOBE NEWSWIRE) -- It just became easier, faster and more efficient to profile the human immune system. Cytek Biosciences Inc., a leading provider of cell analysis solutions, today introduced a 14-color immunoprofiling kit. Featuring a unique combi
Read more →CTKBCytek Biosciences Completes Series D Funding Round
FREMONT, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Cytek Biosciences Inc., a leading provider of cell analysis instrumentation and solutions, today announced that it has closed a $120 million Series D funding round, co-led by RA Capital and Hillhouse Capital, with OrbiMed and LYF
Read more →CTKBCytek Biosciences Receives CE Marking on Its Northern Lights (NL)-CLC Platform
FREMONT, Calif., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Clinical flow cytometry laboratories based in Europe can now go beyond 24 colors – easily and affordably. Cytek Biosciences Inc., a leading provider of cell analysis instrumentation and solutions, today announced that its Cytek®
Read more →CTKBCytek Biosciences Debuts Custom Reagents at CYTO 2020
FREMONT, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- This week at CYTO Virtual 2020, the industry’s premier flow cytometry conference, Cytek Biosciences Inc., a leading provider of cell analysis instrumentation and solutions, will unveil a new family of proprietary reagents. These
Read more →CTKBCytek Biosciences Strengthening Support for Scientists in Fight Against COVID-19
FREMONT, Calif., April 23, 2020 (GLOBE NEWSWIRE) -- Cytek Biosciences Inc., a leading provider of cell analysis instrumentation and solutions, is committed to supporting researchers and clinicians who are now being tasked to study the effect of the novel coronavirus on human immu
Read more →CTKBCytek Biosciences Expands Global Reach
FREMONT, Calif., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Cytek Biosciences Inc.'s mission to make full spectrum flow cytometry accessible to a larger number of scientists continues to resonate with the scientific community. Today, the company announced that its advanced flow cytometry
Read more →CTKBCytek Biosciences Hits Flow Cytometry Milestone: 40 Color Analysis From a Single Sample
FREMONT, Calif., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Flow cytometry’s next chapter is here. Opening the door to deeper immunological insights, Cytek Biosciences Inc., a leading provider of flow cytometry instrumentation, today announced that it has successfully developed and demon
Read more →CTKBCytek Biosciences’ Northern Lights Platform Approved for Clinical Use in China
FREMONT, Calif., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Clinical flow cytometry laboratories based in China can now go beyond 24 colors – easily and affordably. Cytek Biosciences Inc., a leading provider of flow cytometry instrumentation, has received approval from the China National
Read more →CTKBCytek Biosciences Debuts Advanced Five-Laser Flow Cytometer
VANCOUVER, British Columbia, June 19, 2019 (GLOBE NEWSWIRE) -- When five lasers and more than 30 colors combine, new breakthroughs and scientific discoveries take shape. This week at the industry’s premier flow cytometry conference, CYTO 2019, Cytek Biosciences Inc., a leading pr
Read more →CTKBCytek Biosciences Achieves ISO 9001:2015 Certification
FREMONT, Calif., May 16, 2019 (GLOBE NEWSWIRE) -- Cytek Biosciences Inc., a leading provider of advanced flow cytometry instrumentation, today announced that its Quality Management System (QMS) has achieved ISO 9001:2015 certification. The certification applies to Cytek’s headqua
Read more →CTKBCytek Biosciences Adds De Novo Software to Lineup of Advanced Flow Cytometry Systems
FREMONT, Calif., Jan. 08, 2019 (GLOBE NEWSWIRE) -- Cytek Biosciences Inc., a leading provider of flow cytometry instrumentation, today announced that its Aurora and Northern Lights series of flow cytometry systems will now include FCS Express™, a powerful flow cytometry data anal
Read more →CTKBCytek Biosciences Ships 100th Advanced Flow Cytometry System
FREMONT, Calif., Dec. 20, 2018 (GLOBE NEWSWIRE) -- Cytek Biosciences Inc., the preeminent provider of innovative flow cytometry solutions, has marked a significant milestone: the company has shipped 100 of its advanced flow cytometry systems. First introduced in June of last year
Read more →CTKBCytek Biosciences Continues Momentum by Strengthening Executive Team, Adding Board Members
Company’s Advanced Flow Cytometry Systems Being Embraced by Scientists, Clinicians Around the World FREMONT, Calif., Nov. 13, 2018 (GLOBE NEWSWIRE) -- Cytek Biosciences Inc., the preeminent provider of innovative flow cytometry solutions, today announced that Steve Ziganti and P
Read more →CTKBCytek Biosciences Debuts Advanced Flow Cytometry System that Breaks the Cost Barrier
New Northern Lights Series Brings Reagent and Application Flexibility to More Labs – While Enhancing Performance FREMONT, Calif., Oct. 23, 2018 (GLOBE NEWSWIRE) -- The door to discovery has been opened, and the traditional flow cytometry market is set to see a paradigm shift. Wi
Read more →CTKBCytek Biosciences Adds Investors, Completes Series C Financing
FREMONT, Calif., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Cytek Biosciences Inc., the preeminent provider of innovative flow cytometry solutions, today announced the completion of a Series C funding round co-led by Northern Light Venture Capital and 3E Bioventures. The funding will be
Read more →CTKBCytek Biosciences Spotlights the Cytek Aurora Flow Cytometry System at CYTO 2018
PRAGUE, Czech Republic, April 24, 2018 (GLOBE NEWSWIRE) -- This week at the industry’s premier flow cytometry conference, CYTO 2018, Cytek Biosciences Inc. will be on the show floor highlighting its CytekTM Aurora flow cytometry system with enhanced features. This unique platform
Read more →Competitive Position
How CTKB ranks across every disease it competes inCompetitive Position is a premium feature
See how CTKB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial